<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661826</url>
  </required_header>
  <id_info>
    <org_study_id>R39-09-01</org_study_id>
    <nct_id>NCT04661826</nct_id>
  </id_info>
  <brief_title>ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.</brief_title>
  <official_title>ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. A Phase II Marker Lesion. STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fidia Farmaceutici s.p.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fidia Farmaceutici s.p.a.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess, at control visit (V8), the ablative activity of&#xD;
      intravesical administration of Oncofid-P-B on a papillary marker tumor on patients suffering&#xD;
      from multiple primary and recurrent Ta G1-G2 papillary cancer of the bladder after 6 weeks of&#xD;
      weekly study drug administration, through number and percentage of patients with Complete&#xD;
      Response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the preliminary activity of Oncofid-P-B administered by&#xD;
      intravescical route at the Recommended Dose of 600 mg, once a week, for six weeks evaluating&#xD;
      the ablative activity on a papillary marker tumor in patients suffering from non-muscle&#xD;
      invasive cancer of the bladder. When a patient will present a Complete Response at the end of&#xD;
      the six weekly administration of Oncofid-P-B , he/she can enter a second phase of the study&#xD;
      defined maintenance phase. During this phase, the patients will be treated with the study&#xD;
      drug administered by intravesical infusion once a month for 2 cycles of treatment with the&#xD;
      duration of 6 months separated by a period during which study drug will not be administered,&#xD;
      due to the necessity to perform histological evaluation of efficacy. This scheme will follow&#xD;
      a clinical usual approach for the maintenance treatment of patients suffering from non-muscle&#xD;
      invasive cancer of the bladder.&#xD;
&#xD;
      Complete Response is defined as follows: complete disappearance of the marker lesion, as&#xD;
      confirmed by negative post-treatment cystoscopy including a biopsy at the marker lesion site&#xD;
      and the absence of new tumors at other site and negative cytology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2010</start_date>
  <completion_date type="Actual">October 4, 2016</completion_date>
  <primary_completion_date type="Actual">July 29, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR at control visit (V8) after intravescical administration of Oncofid-P-B on a papillary marker tumor.</measure>
    <time_frame>Visit 8 will be performed 2-4 weeks after the last treatment visit (Visit 7)</time_frame>
    <description>Rate of complete response, estimated at V8, after 6 weeks of weekly study drug administration: number and percentage of patients with complete response. Complete response is defined as follows: complete disappearance of the marker lesion, as confirmed by negative post-treatment cystoscopy including a biopsy at the marker lesion site and the absence of new tumors at other sites and negative cytology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse after Oncofid-P-B instillation during the maintenance phase.</measure>
    <time_frame>The second treatment maintenance phase constituted by 2 treatment periods with a duration of 6 months each (comprehensively considered equal to 52 weeks).</time_frame>
    <description>Time to relapse after Oncofid-P-B instillation during the maintenance phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with relapse within V 22.</measure>
    <time_frame>The second treatment maintenance phase constituted by 2 treatment periods with a duration of 6 months each (comprehensively considered equal to 52 weeks).</time_frame>
    <description>Number of patients with relapse within V 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0&quot;</measure>
    <time_frame>The second treatment maintenance phase constituted by 2 treatment periods with a duration of 6 months each (comprehensively considered equal to 52 weeks).</time_frame>
    <description>Treatment-Related Adverse Events as Assessed by CTCAE v4.0&quot; with Oncofid-P-B given by intravesical instillation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-Invasive Papillary Carcinoma of Bladder</condition>
  <arm_group>
    <arm_group_label>Oncofid-P-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncofid-P-B</intervention_name>
    <description>Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.</description>
    <arm_group_label>Oncofid-P-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes aged &gt; 18 years, women in menopause (defined as surgically&#xD;
             sterile or one year postmenopausal);&#xD;
&#xD;
          -  Cytological or histological diagnosis of bladder cancer;&#xD;
&#xD;
          -  Multiple primary or recurrent Ta G1-G2 papillary cancer;&#xD;
&#xD;
          -  ECOG Performance Status 0 to 1;&#xD;
&#xD;
          -  Adequate bone marrow function: neutrophils ≥1.5 103/mL; platelet count ≥100 103/ mm3;&#xD;
             Hb ≥ 10 g/dL;&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Willing and able to comply with the protocol for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to Paclitaxel or one of its constituents;&#xD;
&#xD;
          -  T1 papillary cancer or muscle-invasive disease (T2-T4) ;&#xD;
&#xD;
          -  Previous or concomitant tumor of the upper urinary tract, of the prostatic urethra,&#xD;
             CIS;&#xD;
&#xD;
          -  Any other malignancy diagnosed within 3 years of study entry (except basal or squamous&#xD;
             cell skin cancers or non-invasive cancer of the cervix);&#xD;
&#xD;
          -  Presence of significant urologic disease interfering with intravesical therapy;&#xD;
&#xD;
          -  Participation in another clinical trial with any investigational drug within 30 days&#xD;
             prior to study screening or concurrent treatment with other experimental drugs;&#xD;
&#xD;
          -  Other chemotherapy or radiotherapy within four weeks of study entry;&#xD;
&#xD;
          -  Previous intravesical immunotherapy or chemotherapy less than 3 months before study&#xD;
             entry;&#xD;
&#xD;
          -  Bladder capacity less than 300 mL;&#xD;
&#xD;
          -  Renal and hepatic function values exceeding 2 times the upper normal value;&#xD;
&#xD;
          -  Severe cardiovascular diseases considered a contraindication to intravesical&#xD;
             treatment;&#xD;
&#xD;
          -  Pregnant, lactating or childbearing potential aged women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Urologie, Kinderurologie und Onkologische Urologi</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik und Poliklinik - Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Urologie Rhein-Ruhr</name>
      <address>
        <city>Mülheim</city>
        <zip>D-45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.Universitaria - Ospedale Consorziale Policlinico di Bari - Urologia - Dipartimento d'Emergenza e dei Trapianti di Organi</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia - Dipartimento di Urologia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Pisa - U.O. Urologia Universitaria</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A.Gemelli - Università Cattolica del Sacro Cuore - Dipartimento di Scienze Chirurgiche - Clinica Urologica</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.Città della Salute e della Scienza di Torino - Ospedale Molinette Dipartimento di Urologia I</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <state>Madrid</state>
        <zip>28820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenerife Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologià</name>
      <address>
        <city>Valencia</city>
        <zip>460009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>hyaluronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

